As demonstrated in Figure 2C, animals treated with the non-NAD-like inhibitor 5F02 showed a significant inhibition of tumor growth relative to control animals, i.e., animals treated with the NAD-competitive PARP-1 inhibitor olaparib and animals treated with the multitargeted tyrosine kinase inhibitor sunitinib, a standard agent for the treatment of metastatic RCC [27] (Figure 2C). This evidence concerns the gene PARP1 and neoplasm.